| Name | SymBio Pharmaceuticals Limited | ||
| Address | Toranomon 30 Mori Bldg., 3-2-2 Toranomon, Minato-ku, Tokyo 105-0001, Japan Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 For inquiry about brincidofovir: +81-3-6684-6663 |
||
| Established | March 25, 2005 | ||
| Capital stock | JPY17,530,548,637 (at the end of June 2022) | ||
| Board of Directors | Fuminori Yoshida | Representative Director | |
| Shigetoshi Matsumoto | Board Director <Outside> | ||
| Bruce David Cheson | Board Director <Outside> | ||
| Eiji Ebinuma | Board Director <Outside> | ||
| Kiyoshi Watanabe | Board Director, Full-Time Audit & Supervisory Committee Member<Outside> | ||
| Kesao Endo | Board Director, Audit & Supervisory Committee Member<Outside> | ||
| Yasuhiro Tamo | Board Director, Audit & Supervisory Committee Member<Outside> | ||
| Corporate Officers | Fuminori Yoshida | Corporate Officer, President and Chief Executive Officer | |
| Takaaki Fukushima | Corporate Officer, Chief Financial Officer | ||
| Koji Fukushima | Corporate Officer, Chief Medical Officer | ||
| Kozo Yoshida | Corporate Officer | ||
| Yoshiharu Torikai | Corporate Officer | ||
| Kei Bamba | Corporate Officer | ||
| Subsidiary | SymBio Pharma USA, Inc. Durham, North Carolina, USA Carolyn YanavichPresident and Chief Operating Officer |
||
Privacy Policy | Privacy Notice for Clinical Trials in UK | Terms of Use
Copyright © SymBio Pharmaceuticals Limited. All rights reserved.
